Name: Episode 124: Pharma's lobbying dollars, Alnylam's future, and diversity in Covid-19 studies by STAT
Duration: 26 min 48 s
Description: Is pharma scared of Kamala Harris? Are there second acts in biotech? And why don't Covid-19 trials look more diverse?

This week is a special two-part episode focusing on last week’s controversial — some say inflammatory — decision to approve aducanumab, a new Alzheimer’s drug. In these episodes, I talk with two Alzheimer’s experts with vastly different viewpoints on the news. First up: Dennis J. Selkoe, a physician and scientist whose research is at the core of how Aduhelm works.

Episode 19, Part 1: An original believer on the aducanumab decision

Is pharma scared of Kamala Harris? Are there second acts in biotech? And why don't Covid-19 trials look more diverse?

Episode 124: Pharma's lobbying dollars, Alnylam's future, and diversity in Covid-19 studies

STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.

Episode 124: Pharma's lobbying dollars, Alnylam's future, and diversity in Covid-19 studies

STAT

Related tracks